Does doxepin (tricyclic antidepressant) cause renal failure or metabolic encephalopathy?

Doxepin and Kidney Failure or Metabolic Encephalopathy

Doxepin does not directly cause kidney failure but requires caution in renal impairment; it can contribute to metabolic encephalopathy, particularly through CNS toxicity and anticholinergic effects.

Kidney Effects

The FDA labeling for doxepin explicitly states that "the extent of renal excretion of Doxepin has not been determined" and recommends that "because elderly patients are more likely to have decreased renal function, care should be taken in dose selections" 1. This indicates doxepin is not primarily renally cleared, but dose adjustment may be prudent in renal dysfunction.

Evidence on Renal Toxicity

• Animal studies show doxepin can exacerbate renal damage in the context of metabolic stress. In obese mice, doxepin (5 mg/kg/day for 8 weeks) significantly increased blood urea nitrogen and creatinine levels, worsened renal injury markers (increased reactive oxygen species and inflammatory markers), and decreased antioxidant enzymes 2.

• Systematic reviews of psychotropic drugs found that antidepressants, including tricyclics like doxepin, were not associated with acute or chronic kidney harms in human studies 3. The review concluded antidepressants "do not have clear kidney adverse effects and appear safe" in kidney disease settings.

• However, second-generation antidepressants (not tricyclics specifically) can cause hyponatremia via SIADH, which may indirectly affect renal function 4.

Clinical interpretation: Doxepin is not nephrotoxic in the traditional sense but may worsen pre-existing renal impairment through indirect mechanisms (oxidative stress, metabolic effects). It does not cause primary kidney failure.

Metabolic Encephalopathy

Doxepin can definitely contribute to or cause metabolic/toxic encephalopathy, particularly in overdose or chronic toxicity situations.

Mechanisms and Evidence

The FDA label lists extensive CNS effects including:

• Confusion, disorientation, hallucinations
• Drowsiness, sedation
• Seizures
• Ataxia, tremor
• Numbness, paresthesias 1

Critical case report: A 10-year-old boy developed chronic doxepin toxicity that masqueraded as epilepsy with confusion, ataxia, and seizures. His doxepin-nordoxepin level was 1419 ng/mL (therapeutic 100-300 ng/mL). All symptoms, including seizures, completely resolved after doxepin discontinuation 5. This demonstrates doxepin's capacity to cause severe encephalopathy.

Overdose Presentations

In acute overdose, the FDA label describes "critical manifestations" including:

• CNS depression to coma
• Confusion and disturbed concentration
• Visual hallucinations
• Agitation or stupor
• Seizures 1

A fatal doxepin intoxication case showed very high myocardial tissue concentrations, emphasizing the drug's tissue distribution and toxicity potential 6.

Clinical Recommendations

Monitoring in Renal Impairment

• Start at low doses in patients with renal dysfunction
• Monitor for accumulation signs (increased sedation, confusion)
• Consider dose reduction by 25-50% in moderate-to-severe renal impairment
• No specific laboratory monitoring required beyond standard renal function tests

Recognizing Encephalopathy

Watch for:

• Progressive confusion or altered mental status
• New-onset seizures (especially if no prior epilepsy)
• Ataxia, tremor, or movement disorders
• Anticholinergic symptoms (dry mouth, urinary retention, blurred vision)
• QRS prolongation on ECG (>100 ms suggests toxicity) 1

Risk Factors for Toxicity

The pediatric case identified three key factors 5:

1. Supratherapeutic dosing (>3 mg/kg in children; >150 mg/day single dose in adults per FDA)
2. Drug interactions with CYP2D6 inhibitors (e.g., clobazam, SSRIs) or CYP2C19 inhibitors (e.g., topiramate)
3. Pharmacogenomic variability (CYP2D6 intermediate/poor metabolizers)

Common Pitfalls

• Mistaking chronic doxepin toxicity for primary neurologic disease (epilepsy, dementia) rather than drug effect
• Overlooking drug-drug interactions that inhibit doxepin metabolism
• Inadequate dose reduction in elderly or renally impaired patients
• Not checking doxepin levels when encephalopathy is unexplained (therapeutic range 100-300 ng/mL combined doxepin-nordoxepin)

Management of Suspected Toxicity

1. Obtain ECG immediately (QRS >100 ms indicates significant toxicity)
2. Check serum doxepin levels if available
3. Discontinue doxepin if toxicity suspected
4. Provide supportive care (airway protection if altered consciousness)
5. Use sodium bicarbonate for QRS widening or dysrhythmias (target pH 7.45-7.55) 1
6. Benzodiazepines for seizures (physostigmine NOT recommended) 1

The evidence strongly supports that while doxepin does not cause primary kidney failure, it requires dose adjustment in renal impairment and can definitely cause toxic-metabolic encephalopathy through direct CNS effects, particularly in overdose, chronic toxicity, or with drug interactions.